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Abstract
Background: Centralisation of thrombolysis may offer substantial benefits. The aim of this study was to assess short
term costs and effects of centralisation of thrombolysis and optimised care in a decentralised system.
Methods: Using simulation modelling, three scenarios to improve decentralised settings in the North of Netherlands
were compared from the perspective of the policy maker and compared to current decentralised care: (1) improving
stroke care at nine separate hospitals, (2) centralising and improving thrombolysis treatment to four, and (3) two
hospitals. Outcomes were annual mean and incremental costs per patient up to the treatment with thrombolysis,
incremental cost-effectiveness ratio (iCER) per 1% increase in thrombolysis rate, and the proportion treated with
thrombolysis.
Results: Compared to current decentralised care, improving stroke care at individual community hospitals led to mean
annual costs per patient of $US 1,834 (95% CI, 1,823–1,843) whereas centralising to four and two hospitals led to $US
1,462 (95% CI, 1,451–1,473) and $US 1,317 (95% CI, 1,306–1,328), respectively (P < 0.001). The iCER of improving
community hospitals was $US 113 (95% CI, 91–150) and $US 71 (95% CI, 59–94), $US 56 (95% CI, 44–74) when
centralising to four and two hospitals, respectively. Thrombolysis rates decreased from 22.4 to 21.8% and 21.2%
(P = 0.120 and P = 0.001) in case of increasing centralisation.
Conclusions: Centralising thrombolysis substantially lowers mean annual costs per patient compared to raising
stroke care at community hospitals simultaneously. Small, but negative effects on thrombolysis rates may be
expected.
Keywords: Stroke, Simulation models, Organisational model, Costs, Thrombolysis
Background
Treatment with thrombolysis or tissue plasminogen
activator (tPA) in stroke centres as part of a centralised
organisational model is associated with better patient
outcomes and higher thrombolysis rates compared to
community hospitals in a decentralised model [1]. In
addition to better patient outcomes, centralisation of
thrombolysis may lead to substantial cost-savings [2, 3].
Compared to stroke care at community hospitals,
admission to a stroke centre was associated with an in-
cremental cost-effectiveness ratio of US$ 24,000 per
quality-adjusted life year gained [4]. For every 5%
absolute increase in thrombolysis rates, an additional
30,000 patients annually may be treated within a US
region containing 109 designated stroke centres. Within
the Netherlands, a Breakthrough Series-based imple-
mentation program increased thrombolysis use and
saved short- and long-term healthcare costs due to lower
hospital admission and residential costs, and increasing
stroke care efficiency [5]. The short-term costs and
resource implications associated with advancing com-
munity hospital stroke care to the standards of a stroke
centre however remain unclear, hampering broad imple-
mentation of thrombolysis.
Because distances to hospitals offering thrombolysis in
the Netherlands are relatively short [6], decentralised
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stroke systems may be improved in two ways: (1) raising
stroke care to the standards of a stroke centre in all
individual community hospitals simultaneously, and (2)
centralising and simultaneously improving thrombolysis
treatment thereby reducing the number of community
hospitals offering thrombolysis. Prior to large-scale
implementation, the clinical, financial and personnel
implications of both scenarios should be assessed. In
addition, because the efficacy of thrombolysis is strongly
time-dependent (i.e., the sooner the better) [7], we con-
sidered how time to treatment and travel time to the
hospital would influence patient outcomes.
Using a simulation model, the aims of this study were:
(1) to estimate the short-term costs, up to treatment
with tPA, and the incremental cost-effectiveness ratio
associated with raising stroke care at all community
hospitals simultaneously compared to centralisation of
thrombolysis treatment and (2) to estimate the effects of
centralisation on the average days of extra healthy life,
proportion of patients treated with thrombolysis, total
process time, and travel time.
Methods
The present study was based on a previously published
6-month prospective study on a centralised (n = 280 of
which 124 thrombolysis candidates) and decentralised
(n = 801 of which 227 thrombolysis candidates) organisa-
tional model of acute stroke care within a Dutch region
[1]. A summary on patient recruitment, baseline patient
characteristics, population densities, and access to
healthcare services is provided elsewhere [1]. Variables
were obtained from patients admitted to hospitals
during a 6 month prospective study from February to
July 2010. Data collection focused on time delays along
both the pre- and intrahospital acute stroke pathway,
and on diagnostic accuracy such as choice for first
responder and ambulance transportation.
Organisational models of acute stroke care
In the North of the Netherlands, a centralised and
decentralised organisational model co-exist. The decen-
tralised model comprises nine community hospitals in
which tPA treatment is provided to patients in their
catchment area. Community hospitals included in this
study were medium to large hospitals with 100 to 400
stroke patients admitted per year. University Medical
Centre Groningen (UMCG) acting as stroke centre
served as an example of centralised stroke care. Acute
stroke pathway set-up was identical for both organisa-
tional models. The stroke centre has 24-h, 7-day acute
stroke care coverage, including immediate access to neu-
roimaging (CT, Computed Tomography scan) and exam-
ination at the Emergency Department (ED). Within all
hospitals offering thrombolysis, treatment was given
within a stroke unit according to identical protocols for
tPA treatment (adjusted ECASS III) [8]. Distances and
access to healthcare services such as General Practi-
tioners (GP) offices and Emergency Medical Services
(EMS) are typically short. EMS protocols were available
for GP offices, ambulance dispatch centres and ambu-
lance personnel [9, 10]. The population density and dis-
tribution were roughly similar for the centralised- and
decentralised organisational models, i.e., 250 and 190 in-
habitants per km2, respectively. Within the region a
well-developed and thin branched road network exists
with minimal traffic congestion.
Simulation model
A discrete-event simulation model was designed using
Plant Simulation software [11] to replicate current prac-
tice of community hospitals based on parameter estima-
tions obtained in the prospective study [1]. A previously
developed simulation model was used and extended to
represent input data from the decentralised model [12].
Acute stroke pathway set-up is depicted in Fig. 1. Time
Fig. 1 Acute stroke pathway. All key activities that were modeled are depicted
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delays and diagnostic processes were modeled along the
pre-hospital and in-hospital stroke pathway using
statistical distributions as observed (Table 1). Statistical
distributions were determined (fitted) using ExpertFit
[13, 14]. Costs associated with resource use were
accounted for in the model. Compared to current decen-
tralised care, three scenarios for improving decentralised
stroke care were considered from the perspective of the
policy maker: (1) simultaneously improving stroke care
at all community hospitals, (2) centralisation and im-
provement of acute stroke care in four, and (3) in two
community hospitals, thereby reducing the number of
community hospitals offering thrombolysis (Fig. 2). The
community hospitals hypothetically acting as stroke
centres were chosen based on their geographical location
within a region. The UMCG also participated in these
scenarios as stroke centre. For the last two scenarios the
effect of centralisation on travel time to the treating
hospital was assessed. In all scenarios the level of stroke
care at hospitals was assumed to rise to the performance
of the centralised model; i.e., 22% of all ischaemic stroke
patients would be administered thrombolysis [1].
Centralisation only affects those patients for whom delay
from stroke onset to the moment of transportation is
within the window of opportunity for tPA treatment,
i.e., within 4.5 h. All patients facing a delay of more than
4.5 h were sent to the nearest community hospital.
Improvements associated with centralisation of
thrombolysis treatment were implemented in the simu-
lation model. Pre-hospital factors modeled included:
lapse between stroke onset and call for help, GP consult-
ation, EMS use, and high priority ambulance trans-
portation (i.e., arrival within 15 min after alert). Data
collected in the prospective study included the travel
time from the exact geographical location of the patient
to the hospital providing thrombolysis for all patients
transported by EMS. In-hospital factors included time
from hospital arrival to neurological examination, neuro-
imaging (CT scan), laboratory examination, and treat-
ment with thrombolysis. In the model 10,000 patients
progressed along the stroke pathway. Additional file 1:
Tables S1 and S2 describe model parameters for the im-
proved decentralised model (9 hospitals), and effects of
centralisation on choice of distributions representing pa-
tient transport from the incident scene to a designated
hospital (4, 2 hospitals). Further details on simulation
methodology, model validation, and model data are
provided in Additional file 1: Methods.
Cost calculation
The costs associated with resource use along the stroke
pathway for fixed and variable costs are presented in
Table 2. Short-term costs up to treatment with thromb-
olysis were considered, because these were available.
Data was collected on resource use at the level of all
individual patients in both the pre-hospital and intra-
hospital phase of the stroke pathway. Unit costs were
entered into the simulation model and contributed to
overall resource use.
Mean and incremental annual costs per patient were
estimated for all scenarios including fixed and variable
costs. Fixed costs were considered constant whereas
variable costs fluctuated directly with patient volumes.
Fixed costs included recurring annual public education
campaigns and staff education. The purchase of a new
CT scanner located in the ED was considered a one-time
investment. Yearly depreciation costs for a new CT scan-
ner were conservatively estimated at 10% of the initial
investment [15]. Variable costs estimated included GP
consultation either by telephone or visit, EMS utilisation,
staff deployment associated with activation of the acute
stroke team including a stroke neurologist, resident
neurology, stroke nurse and treatment with thrombolysis
(alteplase). All patients irrespective of eligibility for
thrombolysis underwent neurological examination, CT
scanning, and laboratory examination, either in the ED
for those arriving within the 4.5 h time window or in the
outpatient clinic. No additional staff deployment (emer-
gency physicians, neurologists, radiologists or nurses)
was anticipated in case of centralisation of thrombolysis,
based on expert judgment. Costs per ambulance ride in-
clude tariffs for emergency transport, EMS dispatch, and
costs per driven kilometer. Costs for deployment of
medical personnel per hour included a 39% bonus for
social gratuity, holiday pay, and other. To allow estimat-
ing annual costs and patient throughput the 6-month
study period was extrapolated to 1 year assuming similar
resource utilisation serving 1602 patients in the decen-
tral model. The costs in euro’s were adjusted to the
current euro-dollar exchange index of 1.12 $US per 1
Euro [16]. Mean resource consumption per patient is
presented in Additional file 1: Table S3.
Travel time and distance
Travel time and distance in case of centralisation of
thrombolysis treatment was assessed by hypothetically
transporting patients from the emergency site to the
nearest hospital offering thrombolysis. Only those pa-
tients transported by EMS were included in this analysis,
because of availability of data on exact geographical lo-
cations for this group. In the scenario of centralisation
of thrombolysis, travel time and distance were calculated
with the use of a Web based route planner (http://rou
te.anwb.nl/routeplanner) as the product of estimated
distances and projected travel speeds, consistent with
strategies used in previous studies [17, 18]. The values
obtained by the Web-based route planner were cor-
rected to represent real-world data, as the route planner
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Table 1 Distributions specifying activity durations and diagnostic characteristics for the current decentralised model
Activity duration (minutes)
Model parameter Distribution: type Parameters
Time from stroke onset to call for help Continuous empirical























911 call Uniform Min (1.00), Max (2.00)
GP consult by telephone Uniform Min (2.00), Max (5.00)
GP consult by visit Triangle Mode (40.00), Min (10.00), Max (30.00)
EMS
Response time









A2 Gamma Alpha (3.36), Beta (4.22)
B Beta Alpha 1 (0.69), Alpha 2 (0.53), a (8.92), b (59.33)
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Table 1 Distributions specifying activity durations and diagnostic characteristics for the current decentralised model (Continued)
Time spent on scene











A2 Lognormal Mean (15.24), St. dev. (7.67)
B Lognormal Mean (15.12), St. dev. (8.14)
Transport time
A1 Beta Alpha1 (1.69), Alpha2 (4.16), a (39.66), b (0.62)
A2 Gamma Alpha (5.53), Beta (2.51)
B Beta Alpha 1 (1.07), Alpha 2 (1.41), a (0.02), b (31.61)
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does not account for faster driving speed achieved by
ambulance transportation.
Outcomes measures
The primary end-points were mean and incremental
costs per patient associated with all scenarios. Incremen-
tal cost-effectiveness ratios (iCERs) concerning the
changes in effects (chance of being thrombolysed) and
costs associated with improvement and centralisation
scenarios vs. the current decentralised model were
calculated. Secondary end-points, using the simulation
model, included Onset to Treatment Time (OTT),
estimations of extra healthy life days calculated using
OTT estimates obtained from the simulation model and
Table 1 Distributions specifying activity durations and diagnostic characteristics for the current decentralised model (Continued)












Treatment decision Triangle Mode (10), Min (5), Max (20)
tPA mixing Constant 5
Diagnostics
Choice of route Discrete empirical Value Frequency
1. EMS transport 1 462
2. In-hospital 2 18
3. Self-transport 3 321
Choice first responder Discrete empirical Value Frequency
1. 911 call 1 184
2. GP consult by phone 2 56
3. GP consult by visit 3 126
EMS transport, level of urgency Discrete empirical Value Frequency
911 call
1. A1 1 92
2. A2 2 7
3. B 3 1
GP consult by telephone
1. A1 1 60
2. A2 2 39
3. B 3 1
GP consult by visit
1. A1 1 47
2. A2 2 42
3. B 3 11
Route 1, 2, and 3 indicate patients transported by emergency medical services, those suffering a stroke in the hospital, and patients arriving by self transport,
respectively; GP General practitioner, EMS Emergency medical services; A1, A2, B indicate normative values for ambulance arrival within 15, 30, and > 30 min from
the 911 call until arrival at the location of the patients, respectively; CT, computed tomography; tPA, tissue plasminogen activator. Neurological examination,
neuroimaging, and laboratory examination are considered parallel activities
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Fig. 2 Acute stroke care set-up scenario’s. Current organisational models for acute stroke care in the Northern part of the Netherlands. Within the
centralised model thrombolysis is only given in the University Medical Centre Groningen acting as a stroke centre. Arrangements were made with
surrounding community hospitals (grey circles) to transport suspected acute stroke patients directly to the stroke centre. The decentralised model
consists of nine community hospital all providing thrombolysis within their catchment area (a). Improving acute stroke care at all community
hospital in the decentralised model to the level of a stroke centre (b). Centralisation of the decentral model from nine to four community
hospitals (c). Centralisation of the decentral model from nine to two hospitals (d)
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recently published results on the effects of reducing
OTT on extra healthy life [19], the effect of additional
travel time in case of centralisation on thrombolysis
rates, those thrombolysed within 1.5 h, and the OTT.
The OTT is of interest because the efficacy of thromb-
olysis is time-dependent, i.e., sooner translates into bet-
ter functional outcome and long-term health benefits
(extra healthy life years), in which each minute reduction
in OTT results in an average 1.8 days of extra healthy
life [20–22]. In addition again based on the OTT we
estimated the functional outcomes in terms of the
modified Rankin scale. The modified Rankin Scale score
is a commonly used scale to measure disability and inde-
pendence in stroke victims [23]. The scale consists of six
grades, from 0 to 5, with 0 corresponding to no symp-
toms and 5 corresponding to severe disability. Further-
more, we performed a sensitivity analysis to determine
how a relative 25% increase or decrease in travel time
would influence results in terms of thrombolysis rates,
those thrombolysed within 1.5 h, and the OTT.
Analysis
Costs were assessed separately and presented as means
with their corresponding 95% CIs for all scenarios.
iCER confidence intervals were estimated using a non-
parametric bootstrap method [24], thereby building on
simulation output data available for each of the scenar-
ios. Travel times and distances were presented as
medians with their corresponding 95% CIs. Mann-
Whitney U and Fisher’s exact tests were performed for
continuous and categorical variables. SPSS 20.0 for
Windows software package (Chicago, IL) was used. A
p-value < 0.05 was considered statistically significant.
Informed consent
Informed consent was obtained from all subjects partici-
pating in the prospective study [1] and extended for
current use. The study was approved by the institutional
review board of UMCG.
Results
Primary outcomes
Mean annual costs per patient for current decentralised
care are $US 922 (95% CI, 911–934). Compared to
current decentralised care, improving stroke care at
community hospitals separately led to mean annual costs
per patient of $US 1,834 (95% CI, 1,823–1,843). Centralis-
ing thrombolysis led to a mean annual costs of $US 1,462
(95% CI, 1,451–1,473) when centralising to four, and $US
1,317 (95% CI, 1,306–1,328) when centralising to two
hospitals (P < 0.001), respectively. The iCER for im-
proving stroke care at all nine community hospitals
was $US 113 (95% CI, 91–150) per % increase in
Table 2 Unit costs for resource utilization




Visit by general practitioner $56.00
Emergency medical services transport (2)
Emergency transport $882.00
Dispatch $71.00
Per driven kilometer $5.00
Medical personnel ER visit (1)
Medical specialist (15 min) $44.38
Resident (1 h) $36.48
Nurse (1 h) $35.04
Outpatient clinic visit $89.60 (1)
Computed tomography scan $144.48 (3)
Central laboratory (per test) $27.10 (4)
Alteplase $532.46 (5)
Fixed costs
Public education campaigns (range) $3,750 ($2,500–$5,000) (6)
Staff education (range) $7,500 ($5,000–$10,000) (6)
Computed tomography scan (7)
Purchase computed tomography scan $1,310,000
USD indicates United States dollar; ER, emergency room. (1) Health Care
Insurance Board (CVZ) [31]; (2) Data from regional ambulance services Groningen;
(3) Dirks et al., 2012 [4]; (4) Claes et al., 2006 [32]; (5) www.medicijnkosten.nl;
(6) Alberts et al., 2011 [33]; (7) https://www.medischcontact.nl/nieuws/laatste-
nieuws/artikel/weldoener-koopt-ct-scanner-voor-ziekenhuis.htm
Table 3 Results simulation experiments










Extra healthy life days
(95% prediction interval)b
0. Current decentralised stroke care 14.4% (13.7%–15.1%) 14.3% 70.5% 15.2% 14.7% 134 (131–136)
1. Optimising all 9 Community
hospitals
22.4% (21.6%–23.2%) 27.5% 62.0% 10.5% 26.6% 119 (117–127) 27.0 (13.5–40.5)
2. Centralisation (4 stroke centers) 21.8% (21.0%–22.7%) 25.1% 63.2% 11.7% 25.3% 122 (120–124) 21.6 (10.8–32.4)
3. Centralisation (2 stroke centres) 21.2% (20.4%–22.0%) 21.6% 66.6% 11.9% 23.8% 125 (123–127) 16.2 (8.1–24.3)
tPA indicates tissue plasminogen activator; CI, confidence interval; mRS, modified rankin scale; OTT, onset treatment time
aIndicates the proportion of patients with excellent functional outcome (mRS 0–1) ascribed with thrombolysis treatment [12]
bIndicates the number of additional days in healthy life per minute reduction in OTT [11]
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thrombolysis rate compared to $US 71 (95% CI, 59–
94) and $US 56 (95% CI, 44–72) when centralising to
four and two hospitals.
Secondary outcomes
Table 3 describes the results of the three scenarios per-
formed with the simulation model. Compared to current
decentralised care, optimising stroke care at all nine
community hospitals resulted in an average 27.0 days of
extra of healthy life (95% prediction interval 13.5–40.5),
compared to 21.6 days (95% prediction interval
10.8–32.4) and 16.2 days (95% prediction interval
8.1–24.3) when centralising to four and two stroke
centres, respectively.
Baseline travel times and distances in case of centralisa-
tion are presented as medians with their 95% CIs in
Table 4. Overall, centralisation of thrombolysis treatment
resulted in travel times of 16.0 (95% CI, 3.0–31.9) and
21.2 min (95% CI, 4.0–37.7) in case of four- and two
community hospitals, respectively, compared to 12.0 min
(95% CI, 2.0–30.0) in the baseline model (P < 0.001).
Travel distance increased to 19.7 km (95% CI, 1.1–42.5)
and 26.4 km (95% CI, 1.4–54.5), respectively, com-
pared to 11.6 km, 95% CI, 0.9–31.0) in the baseline
model (P < 0.001).
Sensitivity analysis
In case of centralisation of thrombolysis to four hospitals, a
decrease of 25% in travel time increased the proportion of
patients treated with thrombolysis with 0.4% (from 21.8 to
22.2%, P = 0.544), those thrombolysed within 1.5 h in-
creased from 25.1 to 28.2% (P = 0.021), and OTT decreased
from 121.9 to 119.1 min (P = 0.048). An increase of 25% in
travel time decreased the proportion of patients treated
with thrombolysis by 0.4% (from 21.8 to 21.4%, P = 0.477),
those thrombolysed within 1.5 h decreased from 25.1 to
22.4% (P = 0.038), and the OTT increased from 121.9 to
124.7 min (P = 0.057).
In case of centralisation of thrombolysis to two hospitals, a
decrease of 25% in travel time increased the proportion of
patients treated with thrombolysis with 0.5% (from 21.2 to
21.7%, P= 0.344), those thrombolysed within 1.5 h increased
from 21.6 to 25.1% (P= 0.001), and OTT decreased from
124.5 to 120.9 min (P= 0.001). An increase of 25% in travel
time decreased the proportion of patients treated with
thrombolysis by 0.6% (from 21.2 to 20.6%, P= 0.311),
those thrombolysed within 1.5 h decreased from 21.6 to
19.4% (P= 0.088), and OTT increased from 124.5 to 127.7
(P= 0.027).
Discussion
This study demonstrated that centralisation of thromb-
olysis may lead to substantial annual cost-savings per
patient compared to a scenario in which stroke care
would be improved at all separate community hospitals.
Mean costs were lowest when reducing the number of
community hospitals offering thrombolysis from nine to
two facilities.
The iCER analyses indicated that marginal gains of im-
proving additional community hospitals comes at in-
creasing costs. Furthermore, extended dominance was
observed for the less centralised stroke care scenario.
Estimating the costs associated with a 1% improvement
in tPA treatment rate, and the number needed to treat
of 1 in 7 patients on average keeps out nursing home
(average annual costs well over €50,000) [25], it becomes
clear that the investments required would be quickly
regained. We assumed comparable effects of expediting
thrombolysis treatment on extra healthy life years, i.e.,
1 min reduction in total process time translates into one
additional day of healthy life for each patient treated
with thrombolysis. This was based on similarities be-
tween our population [1] and the one described in the
Table 4 Travel times and distances for the baseline case and centralisation
All patients Optimising all 9 community hospitals Centralisation (4 stroke centres) Centralisation (2 stroke centres)
Estimated travel time
N 446 446 446
Median (95% CI) 12 (2–30) 16 (10–22)† 21 (15–26)†
< 5 min (%) 86 (19) 47 (10) 32 (7)
5–25 min (%) 337 (76) 333 (75) 278 (62)
> 25 min (%) 23 (5) 66 (15) 136 (31)
Estimated travel distance
Median (95% CI) 12 (1–31) 20 (1–43)† 26 (1–55)†
< 5 km (%) 140 (31) 91 (20) 69 (16)
5–25 km (%) 262 (59) 221 (50) 139 (31)
> 25 km (%) 44 (10) 134 (30) 238 (53)
CI indicates confidence interval
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literature [19] in terms of demographics and outcome
distributions (modified Rankin Scale scores). When
compared to a hypothetical optimised decentral system
centralisation of thrombolysis was projected to lead to
small, but statistically significant negative effects on the
proportion patients treated with thrombolysis, OTT, and
fewer additional healthy life years. Whether the better
secondary outcomes attained with the optimised decen-
tral system would outweigh the greater costs in terms of
long-term health and outcomes remains unclear and is
subject of future study. As estimating iCER in terms of
cost per year free of stroke symptoms would rely on
additional assumptions and thus introducing further un-
certainty we refrained from estimating this outcome.
Long-term effects were not taken into consideration as
the long-term consequences slight increases OTT are
difficult to interpret. In any case, this suggests that cen-
tralising thrombolysis treatment should be accompanied
by initiatives to reduce time delays in other parts of the
chain of care; for example by reducing the door-needle-
time. Importantly, thrombolysis rates in a centralised
system would clearly surpass those of current decentra-
lised care. Because of inequalities in geographic and re-
source availability between regions and facilities, our
analysis provides broadly applicable estimates yet might
lack generalisability. However, to account for the poten-
tial effects of, among others, population density, regional
geography, and traffic congestion, and to generalise the
findings presented in this study to other regions, a sensi-
tivity analysis on transport times was performed. The
sensitivity analyses demonstrated that moderate changes
in travel times did not substantially alter results, suggesting
robustness of our findings. In addition, by manipulating
input model parameters, i.e., performing scenario and
sensitivity analyses, for example travel distances, less densely
populated areas could also be represented thus assisting in
optimising the chain of care in other settings as well.
The results of this study corroborate the relevance of
applying organisational models for the configuration of
acute stroke care for a region, instead of local improve-
ments in an individual chain of care. Stroke centre desig-
nation will impact on hospital services in several ways.
First, available resources may be re-distributed if the hos-
pital needs to purchase expensive equipment, hire more
staff, or expand bed capacity. The question whether add-
itional staff is needed to match an increase in patient vol-
umes when thrombolysis treatment is centralised remains
speculative, and further evidence is urgently needed. As-
suming an annual gain in thrombolysis candidates of 16%
as a result of centralisation, staff members may be de-
ployed an additional 256 times annually, from 449 (28% of
1602 stroke patients) to 705 (44% of 1602 patients). In
case the appropriate equipment and staff are already avail-
able, changes may only be necessary in terms of the time
of day staff will be on call, i.e., more hours into a
stroke team. This would imply that the capacity of
stroke centres does not require expanding despite an
increase in patient load. Whether or not this is realis-
tic is subject of further study. Improving coordination
of care through stroke centre designation reduces du-
plication of efforts and redundant diagnostic testing.
In particular, less personnel, work hours, and mate-
rials are needed. Therefore limited hospital budgets
only have to be spent once in a centralised setting in-
stead of raising stroke care at all community hospitals
separately. Furthermore, being a stroke centre likely
will increase the use of other hospital departments
and services, i.e., radiology and laboratory services,
which may result in increased revenues [26].
Unavoidably centralisation leads to longer travel times
from the emergency site to the hospital offering thromb-
olysis. Yet, as demonstrated in a previously published
study this can be compensated by shorter intra-hospital
processes (door-to-needle time) of 35 min compared to
47 min in a decentralised model [1]. In addition, previous
research showed that the door-to-needle time may be fur-
ther shortened to 20 min in optimised settings [27, 28].
We assumed that centralising stroke care may lead to a
doubling of emergency rides by EMS; this would not
require hiring additional EMS personnel or purchasing
additional vehicles. However this too remains a topic for
further study.
Our study has limitations. First, as a short-term time
horizon, i.e., only the costs up to treatment with thromb-
olysis were considered, effects of e.g., postponed therapy
such as long-term sequelae of ischaemic strokes could not
be taken into account. Future studies should try to include
long-term data in their analyses, or use historical data
from review articles. Secondly, costs associated with
thrombolysis such as antithrombotic and lipid lowering
medications were not part of the assessment and could
therefore not be controlled for. Future studies should try
to collect these variables prospectively and include them
in the costs analyses. Third, we mostly used tariffs rather
than societal costs for our analyses. Also, the effects of im-
proved patient outcomes on the frequency and intensity
of informal (family) care should be assessed. An additional
concern is the potential for traffic congestion which might
influence estimated travel times in our study. However, all
patients included in this study had access to 911-systems,
and previous research indicated that traffic patterns only
minimally affects ambulance travel times [29]. Finally, we
did not consider the possibility of misdirecting patients to
decentralised hospitals based on incorrect EMS assess-
ments. However, both recent research [30], and our own
prospective data on the studied region indicate how
suchlike misinterpretations involve only 1–2% of the pa-
tient population.
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Conclusions
Centralisation of thrombolysis leads to substantially lower
annual costs per patient compared to raising the level of
stroke care at community hospitals simultaneously. Small,
but negative effects on average days of healthy life,
thrombolysis rates, and OTT may be expected compared
to optimised decentral care.
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